应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RYZB RayzeBio, Inc.
停牌 02-23 16:00:00 EST
62.49
+0.00
0.00%
最高
62.49
最低
62.49
成交量
0.00
今开
62.49
昨收
62.49
日振幅
0.00%
总市值
37.44亿
流通市值
21.76亿
总股本
5,992万
成交额
1,733万
换手率
0.00%
流通股本
3,482万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
百时美施贵宝第四季度业绩好于预期
Reuters · 02-02
百时美施贵宝第四季度业绩好于预期
未来一天的看点 - 2月2日星期五
Reuters · 02-02
未来一天的看点 - 2月2日星期五
“核药”赛道持续升温 美生物技术公司被溢价100%收购 上市还不到四个月
智通财经 · 2023-12-27
“核药”赛道持续升温 美生物技术公司被溢价100%收购 上市还不到四个月
百时美施贵宝:拟41亿美元收购RayzeBio 加强抗癌药物业务
观点地产网 · 2023-12-27
百时美施贵宝:拟41亿美元收购RayzeBio 加强抗癌药物业务
BUZZ-百时美施贵宝以 40 亿美元收购 RayzeBio,收益翻了一番多
Reuters · 2023-12-27
BUZZ-百时美施贵宝以 40 亿美元收购 RayzeBio,收益翻了一番多
RayzeBio暴涨超100% 获百时美施贵宝溢价104%收购要约
新浪财经 · 2023-12-26
RayzeBio暴涨超100% 获百时美施贵宝溢价104%收购要约
BUZZ-百时美施贵宝斥资 40 亿美元收购 RayzeBio,公司业绩大涨
Reuters · 2023-12-26
BUZZ-百时美施贵宝斥资 40 亿美元收购 RayzeBio,公司业绩大涨
美股异动 | 获施贵宝(BMY.US)41亿美元收购要约 RayzeBio(RYZB.US)
智通财经 · 2023-12-26
美股异动 | 获施贵宝(BMY.US)41亿美元收购要约 RayzeBio(RYZB.US)
开盘 | 美股小幅高开!RayzeBio暴涨100%,亘喜生物涨超60%
老虎资讯综合 · 2023-12-26
开盘 | 美股小幅高开!RayzeBio暴涨100%,亘喜生物涨超60%
盘前 | “妖股”频现!Rayzebio暴涨97%,亘喜生物涨59%;新能源汽车股上涨,理想涨超7%
老虎资讯综合 · 2023-12-26
盘前 | “妖股”频现!Rayzebio暴涨97%,亘喜生物涨59%;新能源汽车股上涨,理想涨超7%
百时美施贵宝将以约41亿美元收购RayzeBio
界面 · 2023-12-26
百时美施贵宝将以约41亿美元收购RayzeBio
美股异动 | Rayzebio盘前暴涨98%,获百时美施贵宝溢价104%收购要约
老虎资讯综合 · 2023-12-26
美股异动 | Rayzebio盘前暴涨98%,获百时美施贵宝溢价104%收购要约
更新版 1-百时美施贵宝将以约 41 亿美元收购 RayzeBio
Reuters · 2023-12-26
更新版 1-百时美施贵宝将以约 41 亿美元收购 RayzeBio
加载更多
公司概况
公司名称:
RayzeBio, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
RayzeBio, Inc.于2020年1月2日在特拉华州成立,总部设在加利福尼亚州圣地亚哥。该公司正在建立一家垂直整合的放射性药物治疗公司。该公司在3期临床试验中领导项目。该公司在具有重大市场机会的治疗领域创建了多种候选药物的管道。该公司最初的重点是建立一个市场领先的生长抑素受体2型,或SSTR2,专营权。随着针对SSTR2的多种诊断和治疗商业产品的出现,它是一种在多种实体瘤中表达的经临床验证的靶点。该公司的主要候选药物RYZ101被设计用于向过度表达SSTR2的肿瘤递送一种高效的α粒子放射性同位素Actinium 225或Ac225。RYZ101由与Ac225结合的多肽结合剂DOTATATE和螯合剂组成。美国食品和药物管理局(FDA)已批准将DOTATATE用作SSTR2诊断成像和治疗剂的多肽结合剂。
发行价格:
--
{"stockData":{"symbol":"RYZB","market":"US","secType":"STK","nameCN":"RayzeBio, Inc.","latestPrice":62.49,"timestamp":1708722000000,"preClose":62.49,"halted":3,"volume":0,"delay":0,"floatShares":34819731,"shares":59919502,"eps":-8.766259,"marketStatus":"停牌","marketStatusCode":0,"change":0,"latestTime":"02-23 16:00:00 EST","open":62.49,"high":62.49,"low":62.49,"amount":17332645.682583,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.766259,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721289600000},"adr":0,"listingDate":1694750400000,"adjPreClose":62.49,"volumeRatio":0},"requestUrl":"/m/hq/s/RYZB","defaultTab":"news","newsList":[{"id":"2408044186","title":"百时美施贵宝第四季度业绩好于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408044186","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408044186?lang=zh_cn&edition=full","pubTime":"2024-02-02 19:59","pubTimestamp":1706875153,"startTime":"0","endTime":"0","summary":" Michael Erman 路透2月2日 - 制药商百时美施贵宝 周五公布的第四季度业绩好于预期,原因是其贫血症新药Reblozyl和已退出专利的血癌药物Revlimid的销售业绩超过了华尔街的预测。该公司去年底宣布了一系列交易,以重新储备其产品线,并表示其第四季度收入为 114.8 亿美元。百时美施贵宝预计,随着癌症免疫疗法Opdivo和血液稀释剂Eliquis失去专利保护,这两种畅销药物在本十年晚些时候的销售额将有所下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670710661.SGD","BK4535","LU1571399168.USD","BK4559","IE00BJT1NW94.SGD","LU1989771016.USD","LU1291159041.SGD","LU1585245621.USD","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU1261432733.SGD","LU0237698245.USD","LU0456855351.SGD","LU1670711123.USD","LU0061475181.USD","LU0882574055.USD","LU1430594728.SGD","LU0321505439.SGD","LU0114720955.EUR","LU0321505868.SGD","LU2125154935.USD","RYZB","IE00BFTCPJ56.SGD","BK4139","BK4588","LU1670711040.USD","BK4585","IE00B2B36J28.USD","LU2242646821.SGD","LU1074936037.SGD","BK4534","IE00BSNM7G36.USD","BK4532","IE0009355771.USD","LU1032466523.USD","LU2242652126.USD","BMY","LU1718418525.SGD","LU2133065610.SGD","LU2125154778.USD","KRTX","IE0002141913.USD","BK4007","LU1670710588.SGD","BK4581","LU0868494617.USD"],"gpt_icon":0},{"id":"2408061665","title":"未来一天的看点 - 2月2日星期五","url":"https://stock-news.laohu8.com/highlight/detail?id=2408061665","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408061665?lang=zh_cn&edition=full","pubTime":"2024-02-02 03:45","pubTimestamp":1706816727,"startTime":"0","endTime":"0","summary":"根据 LSEG 的估计,受能源价格影响,全年净利润预计为 374 亿美元,低于 2022 年的 591 亿美元。预计 1 月份非农就业岗位将增加 180,000 个,12 月份为 216,000 个。1 月份的失业率可能从 12 月份的 3.7% 上升至 3.8%。同时,1 月份平均时薪预计将增长 0.3%,12 月份为增长 0.4%。工资同比增幅可能为 4.1%,与上月持平。另外,美国商务部人口普查局的数据预计将显示,12 月份工厂订单增长 0.2%,而 11 月份为增长 2.6%。医疗保险公司 Cigna Group 预计将公布第四季度财报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BMY","LU0456855351.SGD","LU0130103400.USD","LU1244550221.USD","LU1670711040.USD","IE00B2B36J28.USD","LU0114720955.EUR","BK4532","LU1074936037.SGD","LU0795875169.SGD","LU0175139822.USD","IE0004445239.USD","LU0122379950.USD","LU0980610538.SGD","BK4535","LU1201861165.SGD","LU1496350502.SGD","LU2023250504.SGD","LU2265009873.SGD","LU0109394709.USD","LU1983260115.SGD","LU1201861249.SGD","LU1496350171.SGD","LU1989772923.USD","RYZB","CVX","REGN","LU0648001328.SGD","LU1839511570.USD","LU1267930490.SGD","SG9999014898.SGD","BK4533","LU1989772840.SGD","XOM","AON","LU1804176565.USD","LU0122376428.USD","LU0310799852.SGD","IE0009355771.USD","CHD","BK4534","LU1551013342.USD","ABBV","KRTX","LU2242652126.USD","SG9999014880.SGD","CHTR","CI","LU1732799900.SGD"],"gpt_icon":0},{"id":"2394734000","title":"“核药”赛道持续升温 美生物技术公司被溢价100%收购 上市还不到四个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2394734000","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394734000?lang=zh_cn&edition=full","pubTime":"2023-12-27 23:47","pubTimestamp":1703692021,"startTime":"0","endTime":"0","summary":"当地时间周二,跨国生物医药巨头百时美施贵宝宣布,其与生物技术公司RayzeBio, Inc.达成最终并购协议。协议显示,BMS将以每股62.50美元的价格收购RayzeBio,交易总价值约41亿美元。RayzeBio与“核药”据了解,本次让BMS溢价100%收购的RayzeBio是一家“放射性药物治疗”公司,专注于利用放射性同位素开发抗癌药物。仅上市不到四个月值得一提的是,RayzeBio是一家非常年轻的公司,成立于2020年。今年9月,RayzeBio以每股18美元的价格IPO上市,首日便收涨33%至每股24美元。","market":"sh","thumbnail":"http://imgcloud.jrjimg.cn/2023/12/cms_20231227234701868.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2023/12/cms_20231227234701868.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/27234738902630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4139","RYZB","RPT","BK4080","BK4231"],"gpt_icon":0},{"id":"2394519788","title":"百时美施贵宝:拟41亿美元收购RayzeBio 加强抗癌药物业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2394519788","media":"观点地产网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394519788?lang=zh_cn&edition=full","pubTime":"2023-12-27 16:01","pubTimestamp":1703664069,"startTime":"0","endTime":"0","summary":"观点网讯:12月27日, 百时美施贵宝 日前表示,将以约41亿美元收购RayzeBio,即以每股62.50美元的现金大幅溢价收购,以加强其 抗癌药物 业务。通过这笔交易,百时美施贵宝将获得RayzeBio的晚期靶向癌症疗法RYZ101,该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用。据悉,此前百时美施贵宝同意以140亿美元收购精神分裂症药物开发商Karuna Therapeutics。百时美施贵宝于1982年进入中国市场,成立了改革开放后第一家中美合资制药企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231227161740817fdcc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0114720955.EUR","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU2242652126.USD","BK4559","LU1670711040.USD","LU1670711123.USD","LU1430594728.SGD","BK4139","BK4588","BK4532","LU2125154778.USD","LU0882574055.USD","LU0321505439.SGD","RYZB","BK4534","LU1670710661.SGD","IE00BJT1NW94.SGD","LU0321505868.SGD","LU0868494617.USD","LU1291159041.SGD","LU1670710588.SGD","LU0237698245.USD","LU1261432733.SGD","LU2360032135.SGD","LU2125154935.USD","IE00B2B36J28.USD","LU1585245621.USD","BK4581","IE00BSNM7G36.USD","BK4585","BMY","LU2133065610.SGD","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0061475181.USD","LU1989771016.USD","LU0456855351.SGD","IE0009355771.USD","LU1032466523.USD","BK4007","IE0002141913.USD","LU1718418525.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2394424020","title":"BUZZ-百时美施贵宝以 40 亿美元收购 RayzeBio,收益翻了一番多","url":"https://stock-news.laohu8.com/highlight/detail?id=2394424020","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394424020?lang=zh_cn&edition=full","pubTime":"2023-12-27 00:12","pubTimestamp":1703607137,"startTime":"0","endTime":"0","summary":"(更新) 12月26日 - ** RayzeBio 股价上涨一倍多,达到 61.17美元** 百时美施贵宝 称 ,将以约41亿美元现金收购RYZB;BMY股价下跌1.5%。** BMY 的报价为 62.50 美元/每小时,比 RYZB 的最后收盘价溢价 104.4%。** 包括盘中走势在内,RYZB 的股价自 9 月份上市以来已上涨了约156%,而 BMY 的股价则在过去一年中下跌了近 29%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU1670710661.SGD","LU2125154778.USD","LU0237698245.USD","BK4007","LU2125154935.USD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4581","LU1430594728.SGD","RYZB","LU1291159041.SGD","IE00BJJMRZ35.SGD","BK4559","LU0456855351.SGD","BMY","LU1670711123.USD","LU2360032135.SGD","BK4534","LU1718418525.SGD","BUZZ","IE00BFTCPJ56.SGD","LU1032466523.USD","LU1670710588.SGD","LU2242652126.USD","LU1571399168.USD","IE00B2B36J28.USD","BK4532","LU0114720955.EUR","LU0061475181.USD","IE0009355771.USD","BK4588","LU0868494617.USD","LU1989771016.USD","LU2133065610.SGD","LU0321505868.SGD","LU1670711040.USD","BK4139","LU1261432733.SGD","LU1585245621.USD","BK4585","LU0882574055.USD","LU2242646821.SGD","IE0002141913.USD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2394247183","title":"RayzeBio暴涨超100% 获百时美施贵宝溢价104%收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2394247183","media":"新浪财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394247183?lang=zh_cn&edition=full","pubTime":"2023-12-26 23:18","pubTimestamp":1703603921,"startTime":"0","endTime":"0","summary":"来源:格隆汇\n放射性药物治疗公司RayzeBio(RYZB.US)暴涨超100%,报61.37美元。消息面上,百时美施贵宝将以每股62.5美元(较上周五的收盘价30.57美元溢价104%)的现金收购RayzeBio,以加强其抗癌药物业务。交易价值约41亿美元。\n\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:郭明煜","market":"us","thumbnail":"http://n.sinaimg.cn/spider20231226/622/w350h272/20231226/a139-3f76d0cb66a8aa2bc885981715ad7990.jpg","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/spider20231226/622/w350h272/20231226/a139-3f76d0cb66a8aa2bc885981715ad7990.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2023-12-26/doc-imzzkitp9398009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU1261432733.SGD","BK4581","IE00BFTCPJ56.SGD","LU1670711040.USD","IE00BJT1NW94.SGD","BK4585","LU1718418525.SGD","BK4532","BK4139","LU0321505439.SGD","LU0321505868.SGD","LU1989771016.USD","LU2125154778.USD","LU2125154935.USD","LU2242652126.USD","IE0002141913.USD","LU0114720955.EUR","LU1074936037.SGD","BK4007","LU1670710588.SGD","BK4534","LU2360032135.SGD","LU0061475181.USD","LU1291159041.SGD","BK4559","BK4588","LU0237698245.USD","LU1430594728.SGD","RYZB","IE00BSNM7G36.USD","LU1032466523.USD","LU2133065610.SGD","LU1670711123.USD","LU2242646821.SGD","LU1585245621.USD","LU1670710661.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU0868494617.USD","BMY","LU0882574055.USD"],"gpt_icon":0},{"id":"2394624264","title":"BUZZ-百时美施贵宝斥资 40 亿美元收购 RayzeBio,公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2394624264","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394624264?lang=zh_cn&edition=full","pubTime":"2023-12-26 22:51","pubTimestamp":1703602268,"startTime":"0","endTime":"0","summary":"(更新) 12月26日 - ** RayzeBio 早盘股价上涨一倍多,至 61.65美元** 百时美施贵宝 称 (link),将以约41亿美元现金收购RYZB。** BMY 的出价为 62.50 美元/每小时,比 RYZB 的最后收盘价溢价 104.4 ** 包括盘中走势在内,RYZB 股价自 9 月份首次公开募股以来已上涨约156.88","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1074936037.SGD","LU2360032135.SGD","BK4534","LU1430594728.SGD","LU0061475181.USD","LU0237698245.USD","LU0868494617.USD","LU0114720955.EUR","LU1261432733.SGD","LU2242652126.USD","BK4559","LU2133065610.SGD","IE00BSNM7G36.USD","LU1989771016.USD","LU1291159041.SGD","BK4581","LU1670710588.SGD","BUZZ","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1571399168.USD","LU1670711123.USD","BK4588","LU1670711040.USD","IE00BFTCPJ56.SGD","BK4532","IE0009355771.USD","LU0321505868.SGD","IE00B2B36J28.USD","LU1718418525.SGD","RYZB","BK4007","LU1670710661.SGD","LU1032466523.USD","IE0002141913.USD","LU2242646821.SGD","LU0321505439.SGD","LU2125154778.USD","LU0456855351.SGD","LU0882574055.USD","BK4585","BK4139","BMY","LU2125154935.USD"],"gpt_icon":0},{"id":"2394242677","title":"美股异动 | 获施贵宝(BMY.US)41亿美元收购要约 RayzeBio(RYZB.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2394242677","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394242677?lang=zh_cn&edition=full","pubTime":"2023-12-26 22:38","pubTimestamp":1703601500,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周二,生物制药公司RayzeBio(RYZB.US)股价暴涨,截至发稿,该股涨超101%,报61.57美元。施贵宝(BMY.US)和RayzeBio宣布双方达成最终合并协议。根据协议条款,施贵宝将以每股62.50美元现金收购RayzeBio,总股本价值约41亿美元,以加强其抗癌药物业务。该交易预计将于2024年上半年完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1045505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","LU1989771016.USD","LU2242652126.USD","BK4534","LU0114720955.EUR","LU2133065610.SGD","LU0321505868.SGD","IE0009355771.USD","LU0061475181.USD","IE00B2B36J28.USD","LU0321505439.SGD","LU1670711123.USD","BK4559","BK4581","LU0237698245.USD","BK4139","LU1670711040.USD","IE00BJT1NW94.SGD","LU2125154778.USD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2125154935.USD","LU1571399168.USD","RYZB","LU1032466523.USD","LU2242646821.SGD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1585245621.USD","LU1261432733.SGD","LU1430594728.SGD","LU0868494617.USD","LU1291159041.SGD","LU2360032135.SGD","BK4585","LU1718418525.SGD","BK4532","LU1670710661.SGD","BMY","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU0882574055.USD","BK4588","BK4007"],"gpt_icon":0},{"id":"1160182457","title":"开盘 | 美股小幅高开!RayzeBio暴涨100%,亘喜生物涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160182457","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1160182457?lang=zh_cn&edition=full","pubTime":"2023-12-26 22:30","pubTimestamp":1703601032,"startTime":"0","endTime":"0","summary":"12月26日,美股三大指数集体高开,道指涨0.05%,纳指涨0.24%,标普500指数涨0.10%。网易涨超5%,传暴雪与国内多家游戏厂商洽谈了“国服回归”事宜,最终选择与网易重新牵手合作。英特尔涨近2%。该公司将获得32亿美元政府拨款用于新建250亿美元的以色列芯片工厂。RayzeBio暴涨100%,百时美施贵宝将以约41亿美元总价值大幅溢价收购该公司。亘喜生物涨超60%,阿斯利康以12亿美元收购亘喜生物。新能源汽车中概股普涨,理想汽车涨超7%,蔚来涨超4%,小鹏汽车涨近2%。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4139","GRCL",".SPX","RYZB",".DJI","BK4535"],"gpt_icon":0},{"id":"1103912935","title":"盘前 | “妖股”频现!Rayzebio暴涨97%,亘喜生物涨59%;新能源汽车股上涨,理想涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103912935","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1103912935?lang=zh_cn&edition=full","pubTime":"2023-12-26 20:59","pubTimestamp":1703595557,"startTime":"0","endTime":"0","summary":"此次拟议收购将为阿斯利康的细胞疗法管线增添GC012F CAR-T细胞疗法。盘前行情$亘喜生物$盘前暴涨59%!Rayzebio盘前暴涨97%,据彭博,$施贵宝$将以每股62.50美元现金收购Rayzebio。新能源汽车股盘前普涨,$理想汽车$涨超7%,$蔚来$涨逾4%,$小鹏汽车$涨逾2%。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1720050803.USD","BK1119",".SPX","BK1539",".IXIC","GRCL",".DJI","LI","02015","LU1794554557.SGD","BK1587","BK1575","RYZB","BK4139","BK1588"],"gpt_icon":1},{"id":"2394249943","title":"百时美施贵宝将以约41亿美元收购RayzeBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2394249943","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394249943?lang=zh_cn&edition=full","pubTime":"2023-12-26 20:58","pubTimestamp":1703595502,"startTime":"0","endTime":"0","summary":"百时美施贵宝(Bristol Myers Squibb)12月26日表示,将以约41亿美元收购RayzeBio,以加强其抗癌药物业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312262058227904027b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312262058227904027b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","LU1670710661.SGD","LU2125154778.USD","LU0237698245.USD","BK4007","LU2125154935.USD","LU1074936037.SGD","IE00BSNM7G36.USD","BK4581","LU1430594728.SGD","RYZB","LU1291159041.SGD","IE00BJJMRZ35.SGD","BK4559","LU0456855351.SGD","BMY","LU1670711123.USD","LU2360032135.SGD","BK4534","LU1718418525.SGD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1670710588.SGD","LU1571399168.USD","IE00B2B36J28.USD","BK4532","LU0114720955.EUR","LU0061475181.USD","IE0009355771.USD","BK4588","LU0868494617.USD","LU1989771016.USD","LU2133065610.SGD","LU0321505868.SGD","LU1670711040.USD","BK4139","LU1261432733.SGD","LU1585245621.USD","BK4585","LU0882574055.USD","LU2242646821.SGD","IE0002141913.USD","LU0321505439.SGD"],"gpt_icon":0},{"id":"1140088663","title":"美股异动 | Rayzebio盘前暴涨98%,获百时美施贵宝溢价104%收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=1140088663","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1140088663?lang=zh_cn&edition=full","pubTime":"2023-12-26 20:31","pubTimestamp":1703593893,"startTime":"0","endTime":"0","summary":"12月26日,Rayzebio盘前暴涨98%,据彭博,$施贵宝(BMY)$将以每股62.50美元现金收购Rayzebio。","market":"us","thumbnail":"https://static.tigerbbs.com/a3f00ceb9616da9533f38a065954d799","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a3f00ceb9616da9533f38a065954d799"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","BK4581","RYZB","LU1074936037.SGD","LU1261432733.SGD","BK4588","LU1670711040.USD","LU0061475181.USD","LU2125154935.USD","LU0868494617.USD","LU0321505439.SGD","LU1291159041.SGD","IE0002141913.USD","LU1032466523.USD","BK4559","LU0882574055.USD","LU1670711123.USD","LU1430594728.SGD","LU0321505868.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2394245154","title":"更新版 1-百时美施贵宝将以约 41 亿美元收购 RayzeBio","url":"https://stock-news.laohu8.com/highlight/detail?id=2394245154","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2394245154?lang=zh_cn&edition=full","pubTime":"2023-12-26 20:09","pubTimestamp":1703592545,"startTime":"0","endTime":"0","summary":"(在第 2、3 段增加了详细信息) 路透12月26日 - 百时美施贵宝 周二表示,将以约41亿美元的价格收购放射性药物公司RayzeBio 。布里斯托尔公司表示,它将为每股RayzeBio股票支付62.50美元现金,比股票最后收盘价溢价104%。 交易宣布前,RayzeBio 股票停牌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","LU0321505868.SGD","LU1670711040.USD","BK4139","BK4534","LU1718418525.SGD","IE0009355771.USD","BK4585","IE00B2B36J28.USD","LU2125154778.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU0237698245.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","LU1261432733.SGD","LU1032466523.USD","LU0868494617.USD","BK4581","BK4007","BK4588","IE00BSNM7G36.USD","LU1670710661.SGD","LU1670711123.USD","RYZB","LU2133065610.SGD","LU0114720955.EUR","LU1989771016.USD","BK4532","LU0882574055.USD","LU2360032135.SGD","BK4559","LU2242652126.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU2125154935.USD","IE0002141913.USD","LU1571399168.USD","LU2242646821.SGD","LU1670710588.SGD","LU0061475181.USD","LU1430594728.SGD","LU0456855351.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://rayzebio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0094},{"period":"1year","weight":2.4717},{"period":"ytd","weight":0.0051}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":0.018},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.2262},{"period":"ytd","weight":0.1717}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"RayzeBio, Inc.于2020年1月2日在特拉华州成立,总部设在加利福尼亚州圣地亚哥。该公司正在建立一家垂直整合的放射性药物治疗公司。该公司在3期临床试验中领导项目。该公司在具有重大市场机会的治疗领域创建了多种候选药物的管道。该公司最初的重点是建立一个市场领先的生长抑素受体2型,或SSTR2,专营权。随着针对SSTR2的多种诊断和治疗商业产品的出现,它是一种在多种实体瘤中表达的经临床验证的靶点。该公司的主要候选药物RYZ101被设计用于向过度表达SSTR2的肿瘤递送一种高效的α粒子放射性同位素Actinium 225或Ac225。RYZ101由与Ac225结合的多肽结合剂DOTATATE和螯合剂组成。美国食品和药物管理局(FDA)已批准将DOTATATE用作SSTR2诊断成像和治疗剂的多肽结合剂。","exchange":"NASDAQ","name":"RayzeBio, Inc.","nameEN":"RayzeBio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RayzeBio, Inc.(RYZB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供RayzeBio, Inc.(RYZB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"RayzeBio, Inc.,RYZB,RayzeBio, Inc.股票,RayzeBio, Inc.股票老虎,RayzeBio, Inc.股票老虎国际,RayzeBio, Inc.行情,RayzeBio, Inc.股票行情,RayzeBio, Inc.股价,RayzeBio, Inc.股市,RayzeBio, Inc.股票价格,RayzeBio, Inc.股票交易,RayzeBio, Inc.股票购买,RayzeBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RayzeBio, Inc.(RYZB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供RayzeBio, Inc.(RYZB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}